The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 14, 2015, Pages 2193-2204

  Perugi, Giulio ^a,b   Vannucchi, Giulia ^b  

^a UNIVERSITY OF PISA   (Italy)

^b G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

Author keywords

amphetamine salts; atomoxetine; attention deficit hyperactivity disorder; bipolar disorder; dexmethylphenidate; lisdexamphetmanine; management; methylphenidate; psychopharmacological treatment; stimulants

Indexed keywords

ATOMOXETINE; CENTRAL STIMULANT AGENT; MOOD STABILIZER;

ADULTHOOD; ALCOHOL ABUSE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL PRACTICE; COMORBIDITY; DEPRESSION; DISEASE COURSE; DISEASES; DRUG ABUSE; DRUG EFFICACY; DRUG MISUSE; DRUG SAFETY; EMOTIONAL DISORDER; FOLLOW UP; HUMAN; HYPOMANIA; IRRITABILITY; MALINGERING; MENTAL DISEASE; MENTAL INSTABILITY; MOOD DISORDER; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBSTANCE USE; TREATMENT DURATION; TREATMENT RESPONSE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

ATOMOXETINE HYDROCHLORIDE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; COMORBIDITY; HUMANS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84941342782     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1079620     Document Type: Review

References (132)

1. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 2005; 57 (11): 1442-51
2. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD. An overview. Ann N Y Acad Sci 2001; 931: 1-16
3. Wilens TE, Dodson W. A clinical perspective of attention-deficit/hyperactivity disorder into adulthood. J Clin Psychiatry 2004; 65 (10): 1301-13
4. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163 (4): 716-23
5. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007; 190: 402-9
6. McIntyre RS, Kennedy SH, Soczynska JK, et al. Attention-deficit/hyperactivity disorder in adults with bipolar disorder or major depressive disorder: results from the international mood disorders collaborative project. Prim Care Companion J Clin Psychiatry 2010; 12: 3
7. Nierenberg AA, Miyahara S, Spencer T, et al. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry 2005; 57 (11): 1467-73
8. Ryden E, Thase ME, Straht D, et al. A history of childhood attention-deficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD. Acta Psychiatr Scand 2009; 120 (3): 239-46
9. Tamam L, Karakus G, Ozpoyraz N. Comorbidity of adult attention-deficit hyperactivity disorder and bipolar disorder: prevalence and clinical correlates. Eur Arch Psychiatry Clin Neurosci 2008; 258 (7): 385-93
10. Halmoy A, Halleland H, Dramsdahl M, et al. Bipolar symptoms in adult attention-deficit/hyperactivity disorder: a cross-sectional study of 510 clinically diagnosed patients and 417 population-based controls. J Clin Psychiatry 2010; 71 (1): 48-57
11. Bond DJ, Hadjipavlou G, Lam RW, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry 2012; 24 (1): 23-37
12. Skirrow C, Hosang GM, Farmer AE, et al. An update on the debated association between ADHD and bipolar disorder across the lifespan. J Affect Disord 2012; 141 (2-3): 143-5
13. Wingo AP, Ghaemi SN. A systematic review of rates and diagnostic validity of comorbid adult attention-deficit/hyperactivity disorder and bipolar disorder. J Clin Psychiatry 2007; 68 (11): 1776-84
14. Bernardi S, Cortese S, Solanto M, et al. Bipolar disorder and comorbid attention deficit hyperactivity disorder. A distinct clinical phenotype? Clinical characteristics and temperamental traits. World J Biol Psychiatry 2010; 11 (4): 656-66
15. Karaahmet E, Konuk N, Dalkilic A, et al. The comorbidity of adult attention-deficit/hyperactivity disorder in bipolar disorder patients. Compr Psychiatry 2013; 54 (5): 549-55
16. Wilens TE, Biederman J, Wozniak J, et al. Can adults with attention-deficit/hyperactivity disorder be distinguished from those with comorbid bipolar disorder? Findings from a sample of clinically referred adults. Biol Psychiatry 2003; 54 (1): 1-8
17. Masi G, Perugi G, Toni C, et al. Attention-deficit hyperactivity disorder-bipolar comorbidity in children and adolescents. Bipolar Disord 2006; 8 (4): 373-81
18. Tamam L, Tuglu C, Karatas G, et al. Adult attention-deficit hyperactivity disorder in patients with bipolar I disorder in remission: preliminary study. Psychiatry Clin Neurosci 2006; 60 (4): 480-5
19. Klassen LJ, Katzman MA, Chokka P. Adult ADHD and its comorbidities, with a focus on bipolar disorder. J Affect Disord 2010; 124 (1-2): 1-8
20. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother 2005; 5 (4): 525-39
21. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157 (5): 816-18
22. Torralva T, Gleichgerrcht E, Torrente F, et al. Neuropsychological functioning in adult bipolar disorder and ADHD patients: a comparative study. Psychiatry Res 2011; 186 (2-3): 261-6
23. Biederman J, Wozniak J, Tarko L, et al. Re-examining the risk for switch from unipolar to bipolar major depressive disorder in youth with ADHD: a long term prospective longitudinal controlled study. J Affect Disord 2014; 152-154: 347-51
24. El-Mallakh RS. An open study of methylphenidate in bipolar depression. Bipolar Disord 2000; 2 (1): 56-9
25. Parker G, Brotchie H. Do the old psychostimulant drugs have a role in managing treatment-resistant depression? Acta Psychiatr Scand 2010; 121 (4): 308-14
26. Fawcett J, Kravitz HM, Zajecka JM, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991; 11 (2): 127-32
27. Meyers B. Treatment of imipramine-resistant depression and lithium-refractory mania through drug interactions. Am J Psychiatry 1978; 135 (11): 1420-1
28. Bannet J, Ebstein RP, Belmaker RH. Clinical aspects of the interaction of lithium and stimulants. Br J Psychiatry 1980; 136: 204
29. Drimmer EJ, Gitlin MJ, Gwirtsman HE. Desipramine and methylphenidate combination treatment for depression: case report. Am J Psychiatry 1983; 140 (2): 241-2
30. Schaller JL, Behar D. Treatment of a case of comorbid bipolar disorder and attention-deficit/hyperactivity disorder. J Neuropsychiatry Clin Neurosci 1998; 10 (2): 235-6
31. McIntyre RS, Alsuwaidan M, Soczynska JK, et al. The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. Hum Psychopharmacol 2013; 28 (5): 421-7
32. Findling RL, Short EJ, McNamara NK, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46 (11): 1445-53
33. Scheffer RE, Kowatch RA, Carmody T, et al. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 2005; 162 (1): 58-64
34. Hamrin V, Bailey K. Gabapentin and methylphenidate treatment of a preadolescent with attention deficit hyperactivity disorder and bipolar disorder. J Child Adolesc Psychopharmacol 2001; 11 (3): 301-9
35. Perugi G, Toni C, Frare F, et al. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? J Clin Psychopharmacol 2002; 22 (6): 584-91
36. Castaneda R, Levy R, Hazzi C, et al. Treating adult attention deficit hyperactivity disorder in hospitalized psychiatric patients. Gen Hosp Psychiatry 2008; 30 (6): 572-7
37. Lydon E, El-Mallakh RS. Naturalistic long-term use of methylphenidate in bipolar disorder. J Clin Psychopharmacol 2006; 26 (5): 516-18
38. Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord 2004; 6 (5): 416-20
39. Biederman J, Spencer TJ, Petty C, et al. Longitudinal course of deficient emotional self-regulation CBCL profile in youth with ADHD: prospective controlled study. Neuropsychiatr Dis Treat 2012; 8: 267-76
40. State RC, Frye MA, Altshuler LL, et al. Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania. J Clin Psychiatry 2004; 65 (8): 1057-63
41. Reimherr FW, Williams ED, Strong RE, et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007; 68 (1): 93-101
42. Rosler M, Retz W, Fischer R, et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry 2010; 11 (5): 709-18
43. Retz W, Stieglitz RD, Corbisiero S, et al. Emotional dysregulation in adult ADHD: What is the empirical evidence? Expert Rev Neurother 2012; 12 (10): 1241-51
44. Marchant BK, Reimherr FW, Halls C, et al. OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study. Ann Clin Psychiatry 2010; 22 (3): 196-204
45. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2006; 163 (7): 1149-52
46. Mosholder AD, Gelperin K, Hammad TA, et al. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics 2009; 123 (2): 611-16
47. Kraemer M, Uekermann J, Wiltfang J, et al. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clin Neuropharmacol 2010; 33 (4): 204-6
48. Spensley J. Folie a deux with methylphenidate psychosis. J Nerv Ment Dis 1972; 155 (4): 288-90
49. Spensley J, Rockwell DA. Psychosis during methylphenidate abuse. N Engl J Med 1972; 286 (16): 880-1
50. Young JG. Methylphenidate-induced hallucinosis: case histories and possible mechanisms of action. J Dev Behav Pediatr 1981; 2 (2): 35-8
51. Schneider BN, Enenbach M. Managing the risks of ADHD treatments. Curr Psychiatry Rep 2014; 16 (10): 479
52. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27 (5): 699-711
53. Asherson P, Bushe C, Saylor K, et al. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol 2014; 28 (9): 837-46
54. Chang K, Nayar D, Howe M, et al. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J Child Adolesc Psychopharmacol 2009; 19 (5): 547-51
55. Bahali K, Uneri OS, Ipek H. Atomoxetine-induced mania-like symptoms in an adolescent patient. Actas Esp Psiquiatr 2013; 41 (2): 137-8
56. Hah M, Chang K. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol 2005; 15 (6): 996-1004
57. Henderson TA. Mania induction associated with atomoxetine. J Clin Psychopharmacol 2004; 24 (5): 567-8
58. Henderson TA, Hartman K. Aggression, mania, and hypomania induction associated with atomoxetine. Pediatrics 2004; 114 (3): 895-6
59. Steinberg S, Chouinard G. A case of mania associated with tomoxetine. Am J Psychiatry 1985; 142 (12): 1517-18
60. Reimherr FW, Marchant BK, Strong RE, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry 2005; 58 (2): 125-31
61. Sobanski E, Sabljic D, Alm B, et al. A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD. Pharmacopsychiatry 2012; 45 (3): 100-7
62. Marchant BK, Reimherr FW, Halls C, et al. Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine. Atten Defic Hyperact Disord 2011; 3 (3): 237-44
63. Asherson P, Stes S, Nilsson Markhed M, et al. The effects of atomoxetine on emotional control in adults with ADHD: An integrated analysis of multicenter studies. Eur Psychiatry 2015; 30 (4): 511-20
64. Van Brunt DL, Johnston JA, Ye W, et al. Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data. J Manag Care Pharm 2006; 12 (3): 230-8
65. Katusic SK, Barbaresi WJ, Colligan RC, et al. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol 2005; 15 (5): 764-76
66. Maremmani I, Perugi G, Pacini M, et al. Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm. J Affect Disord 2006; 93 (1-3): 1-12
67. Molina BS, Pelham WE Jr. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol 2003; 112 (3): 497-507
68. Satterfield JH, Hoppe CM, Schell AM. A prospective study of delinquency in 110 adolescent boys with attention deficit disorder and 88 normal adolescent boys. Am J Psychiatry 1982; 139 (6): 795-8
69. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1997; 36 (1): 21-9
70. Mannuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993; 50 (7): 565-76
71. King VL, Brooner RK, Kidorf MS, et al. Attention deficit hyperactivity disorder and treatment outcome in opioid abusers entering treatment. J Nerv Ment Dis 1999; 187 (8): 487-95
72. Levin FR. Diagnosing attention-deficit/hyperactivity disorder in patients with substance use disorders. J Clin Psychiatry 2007; 68 (Suppl 11): 9-14
73. Clure C, Brady KT, Saladin ME, et al. Attention-deficit/hyperactivity disorder and substance use: symptom pattern and drug choice. Am J Drug Alcohol Abuse 1999; 25 (3): 441-8
74. Ceraudo G, Toni C, Vannucchi G, et al. Is substance use disorder with comorbid adult attention deficit hyperactivity disorder and bipolar disorder a distinct clinical phenotype? Heroin Addict Relat Clin Probl 2012; 14 (3): 71-6
75. Kalbag AS, Levin FR. Adult ADHD and substance abuse: diagnostic and treatment issues. Subst Use Misuse 2005; 40 (13-14): 1955-81. 2043-8
76. Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 2005; 35 (2): 245-56
77. Wilens TE, Biederman J, Mick E, et al. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis 1997; 185 (8): 475-82
78. Wise BK, Cuffe SP, Fischer T. Dual diagnosis and successful participation of adolescents in substance abuse treatment. J Subst Abuse Treat 2001; 21 (3): 161-5
79. Stein MT, Marx NR, Beard J Jr, et al. ADHD: the diagnostic process from different perspectives. J Dev Behav Pediatr 2004; 25 (5 Suppl): S54-8
80. Arias AJ, Gelernter J, Chan G, et al. Correlates of co-occurring ADHD in drug-dependent subjects: prevalence and features of substance dependence and psychiatric disorders. Addict Behav 2008; 33 (9): 1199-207
81. Carroll KM, Rounsaville BJ. History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Compr Psychiatry 1993; 34 (2): 75-82
82. Biederman J, Wilens T, Mick E, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152 (11): 1652-8
83. Faraone SV, Biederman J, Mennin D, et al. Attention-deficit hyperactivity disorder with bipolar disorder: a familial subtype? J Am Acad Child Adolesc Psychiatry 1997; 36 (10): 1378-87
84. Perugi G, Ceraudo G, Vannucchi G, et al. Attention deficit/hyperactivity disorder symptoms in Italian bipolar adult patients: a preliminary report. J Affect Disord 2013; 149 (1-3): 430-4
85. Wilens TE, Biederman J, Mick E. Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am J Addict 1998; 7 (2): 156-63
86. Faraone SV, Biederman J. Is attention deficit hyperactivity disorder familial? Harv Rev Psychiatry 1994; 1 (5): 271-87
87. Wozniak J, Biederman J, Kiely K, et al. Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. J Am Acad Child Adolesc Psychiatry 1995; 34 (7): 867-76
88. Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders? J Clin Psychiatry 2003; 64 (Suppl 11): 9-13
89. Wilson JJ. ADHD and substance use disorders: developmental aspects and the impact of stimulant treatment. Am J Addict 2007; 16 (Suppl 1): 5-11
90. Rabiner DL. Stimulant prescription cautions: addressing misuse, diversion and malingering. Curr Psychiatry Rep 2013; 15 (7): 375
91. Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008; 96 (1-2): 145-54
92. Wilens TE, Adler LA, Tanaka Y, et al. Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. Curr Med Res Opin 2011; 27 (12): 2309-20
93. Adler L, Wilens T, Zhang S, et al. Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence. Am J Addict 2009; 18 (5): 393-401
94. Johnston LD, OMalley PM, Bachman JG, et al. Monitoring the Future national survey results on drug use, 1975-2011. College students and adults ages 19-50. Volume II Institute for Social Research, The University of Michigan; Ann Arbor: 2012. p. 314
95. Rabiner DL, Anastopoulos AD, Costello EJ, et al. Motives and perceived consequences of nonmedical ADHD medication use by college students: are students treating themselves for attention problems? J Atten Disord 2009; 13 (3): 259-70
96. Foley R, Mrvos R, Krenzelok EP. A profile of methylphenidate exposures. J Toxicol Clin Toxicol 2000; 38 (6): 625-30
97. Sepulveda DR, Thomas LM, McCabe SE, et al. Misuse of prescribed stimulant medication for ADHD and associated patterns of substance use: preliminary analysis among college students. J Pharm Pract 2011; 24 (6): 551-60
98. Rabiner DL, Anastopoulos AD, Costello EJ, et al. The misuse and diversion of prescribed ADHD medications by college students. J Atten Disord 2009; 13 (2): 144-53
99. Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med 2008; 10 (5): 111
100. Upadhyaya HP, Rose K, Wang W, et al. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Child Adolesc Psychopharmacol 2005; 15 (5): 799-809
101. Stoops WW, Glaser PE, Rush CR. Reinforcing, subject-rated, and physiological effects of intranasal methylphenidate in humans: a dose-response analysis. Drug Alcohol Depend 2003; 71 (2): 179-86
102. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003; 160 (11): 1909-18
103. Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 2003; 23 (10): 1281-99
104. Faraone SV, Wilens TE. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry 2007; 68 (Suppl 11): 15-22
105. Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006; 45 (4): 408-14
106. Kollins SH, Rush CR, Pazzaglia PJ, et al. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 1998; 6 (4): 367-74
107. Teter CJ, McCabe SE, Boyd CJ, et al. Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy 2003; 23 (5): 609-17
108. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse 2004; 39 (7): 1095-116
109. McCabe SE, Knight JR, Teter CJ, et al. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005; 100 (1): 96-106
110. Teter CJ, McCabe SE, Cranford JA, et al. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health 2005; 53 (6): 253-62
111. McCabe SE, Teter CJ. Drug use related problems among nonmedical users of prescription stimulants: a web-based survey of college students from a Midwestern university. Drug Alcohol Depend 2007; 91 (1): 69-76
112. Sullivan BK, May K, Galbally L. Symptom exaggeration by college adults in attention-deficit hyperactivity disorder and learning disorder assessments. Appl Neuropsychol 2007; 14 (3): 189-207
113. Suhr J, Hammers D, Dobbins-Buckland K, et al. The relationship of malingering test failure to self-reported symptoms and neuropsychological findings in adults referred for ADHD evaluation. Arch Clin Neuropsychol 2008; 23 (5): 521-30
114. Novak SP, Kroutil LA, Williams RL, et al. The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy 2007; 2: 32
115. Lee Booksh R, Pella RD, Singh AN, et al. Ability of college students to simulate ADHD on objective measures of attention. J Atten Disord 2010; 13 (4): 325-38
116. Sollman MJ, Ranseen JD, Berry DT. Detection of feigned ADHD in college students. Psychol Assess 2010; 22 (2): 325-35
117. Conners CK. Conners continuous performance test. Ottawa: MultiHealth Systems; 1995
118. Jasinski LJ, Harp JP, Berry DT, et al. Using symptom validity tests to detect malingered ADHD in college students. Clin Neuropsychol 2011; 25 (8): 1415-28
119. Monastra VJ, Lubar JF, Linden M. The development of a quantitative electroencephalographic scanning process for attention deficit-hyperactivity disorder: reliability and validity studies. Neuropsychology 2001; 15 (1): 136-44
120. Snyder SM, Hall JR. A meta-analysis of quantitative EEG power associated with attention-deficit hyperactivity disorder. J Clin Neurophysiol 2006; 23 (5): 440-55
121. Snyder SM, Quintana H, Sexson SB, et al. Blinded, multi-center validation of EEG and rating scales in identifying ADHD within a clinical sample. Psychiatry Res 2008; 159 (3): 346-58
122. Kent L, Craddock N. Is there a relationship between attention deficit hyperactivity disorder and bipolar disorder? J Affect Disord 2003; 73 (3): 211-21
123. Malhi GS, Ivanovski B, Hadzi-Pavlovic D, et al. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord 2007; 9 (1-2): 114-25
124. Dorrego MF, Canevaro L, Kuzis G, et al. A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. J Neuropsychiatry Clin Neurosci 2002; 14 (3): 289-95
125. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111 (1): 179-85
126. Asherson P, Young AH, Eich-Hochli D, et al. Differential diagnosis, comorbidity, and treatment of attention-deficit/hyperactivity disorder in relation to bipolar disorder or borderline personality disorder in adults. Curr Med Res Opin 2014; 30 (8): 1657-72
127. Post RE, Kurlansik SL. Diagnosis and management of adult attention-deficit/hyperactivity disorder. Am Fam Physician 2012; 85 (9): 890-6
128. DelBello MP, Soutullo CA, Hendricks W, et al. Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disord 2001; 3 (2): 53-7
129. Scheffer RE. Concurrent ADHD and bipolar disorder. Curr Psychiatry Rep 2007; 9 (5): 415-19
130. Wilens TE, Adamson J, Sgambati S, et al. Do individuals with ADHD self-medicate with cigarettes and substances of abuse? Results from a controlled family study of ADHD. Am J Addict 2007; 16 (Suppl 1): 14-21
131. Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009; 23 (Suppl 1): 21-31
132. Substance Abuse and Mental Health Sevices Administration. Results from the 2003 National Survey on Drug Use and Health: Detailed Tables. 2004